Venous Thromboembolism Prophylaxis and Treatment in Patients with Cancer
Key Points
Key Points
Patients with cancer are significantly more likely to develop VTE than people without cancer and experience higher rates of VTE recurrence and bleeding complications during VTE treatment.
Comprehensive management of VTE in patients with cancer includes both the identification of patients who are most likely to benefit from pharmacologic prophylaxis, as well as effective treatment to reduce the risk of VTE recurrence and mortality.
The current update adds apixaban as an option for the treatment of VTE in patients with cancer, and addresses recent evidence regarding direct factor Xa inhibitors for extended postoperative thromboprophylaxis.
Treatment
...reatmen...
...patients who have active malignancy an...
...tients who have active malignancy witho...
...cologic thromboprophylaxis should not be...
...e pharmacologic thromboprophylaxis...
...-risk outpatients with cancer (Khorana score [T...
...with multiple myeloma receiving th...
...nts with malignant disease undergoing major s...
...xis with UFH or LMWH should be com...
...hanical methods may be added to pharmacologic...
...mbined regimen of pharmacologic and mechanic...
...ic thromboprophylaxis for patients und...
...pharmacologic thromboprophylaxis for up to 4 wee...
...ed) Patients who are candidates for e...
...ted) Alternatively, patients may be o...
...Updated) Initial anticoagulation may involve LMWH...
...Updated) For long-term anticoagulation, LMWH, e...
...with LMWH, direct factor Xa inhibitors, or VKAs be...
...d on expert opinion in the absence o...
...on of a vena cava filter may be offer...
...atients with primary or metastatic central...
...ntal PE and deep vein thrombosis should be treated...
...olated subsegmental PE or splanchnic or visce...
...icoagulant use is not recommended to i...
...tial variation in risk of VTE between individual c...
...members of the oncology team should...
...ng off-label use in guideline reco...
Table 2. Predictive Model for Chemotherapy-...